Medicare IVIG Access Enhancement Act of 2025
Medicare IVIG Access Enhancement Act of 2025
Plain Language Summary
# Medicare IVIG Access Enhancement Act of 2025 – Plain Language Summary **What the Bill Would Do** This bill would allow Medicare to cover the cost of administering intravenous immune globulin (IVIG) treatments in patients' homes. IVIG is a medical treatment made from antibodies that helps treat two rare nerve diseases: CIDP (chronic inflammatory demyelinating polyneuropathy) and multifocal motor neuropathy. Both conditions cause progressive muscle weakness and numbness.
Currently, Medicare may not fully cover at-home IVIG administration for these conditions, meaning patients might have to receive treatment at hospitals or clinics instead. **Who It Affects** The bill primarily affects Medicare beneficiaries (people 65 and older, plus some younger disabled individuals) who have CIDP or multifocal motor neuropathy. It would also impact healthcare providers who administer these treatments and could reduce out-of-pocket costs for eligible patients. The bill aims to make treatment more convenient and accessible by allowing people to receive care at home rather than traveling to medical facilities. **Current Status** The bill (HR 1143) was introduced in the 119th Congress by Representative Adrian Smith (R-Nebraska) and is currently in committee, meaning it has not yet been debated or voted on by the full House of Representatives.
CRS Official Summary
Medicare IVIG Access Enhancement Act of 2025This bill provides for Medicare coverage of in-home administration of intravenous immune globulin to treat chronic inflammatory demyelinating polyneuropathy (CIDP) or multifocal motor neuropathy. (CIDP is an autoimmune condition that causes symptoms such as muscle weakness and numbness; multifocal motor neuropathy is a variant of CIDP that only causes asymmetric muscle weakness.)
Latest Action
Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.